Study wrapper · #1243
GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.
Editor's note
This is a structured causal-inference review rather than new trial data, and its main value is discipline: it sorts a noisy pharmacovigilance literature through the Bradford Hill criteria instead of tallying case reports. The authors land where most regulators have — plausible mechanisms, insufficient proof of causation — which is a meaningfully calmer read than headlines about GLP-1s and suicidality. As a review, it cannot resolve confounding by indication; obesity and diabetes themselves carry psychiatric comorbidity. Worth reading as a map of open questions, not a safety verdict.
Plain-language abstract
Researchers systematically reviewed whether GLP-1 drugs like semaglutide and dual-action drugs like tirzepatide are genuinely linked to mental-health effects, including depression, anxiety, suicidality, changes in reward behavior, and eye problems. They applied the Bradford Hill criteria, a classic framework for judging whether an association is likely to be causal. The verdict: there are biologically plausible connections between these drugs and the brain, but the evidence is not strong enough to say the drugs actually cause most of the reported psychiatric outcomes.